UNSPSC 51384613: Lonazolac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H13ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 13097143QI, chemically known as 1h-pyrazole-4-acetic acid, 3-(4-chlorophenyl)-1-phenyl- but generally known as lonazolac, which bears US NIH Compound Identifier 68706. European Medicines Agency schedules Lonazolac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08570MIG.

UNSPSC 51384613 Lonazolac is a Commodity code that in recent state and local procurement activity captures purchases of pharmaceutical products and related health-system supplies, though the recent opportunities tagged to this code show limited direct alignment with lonazolac specifically. Seminole County, Florida issued an IFB in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 for generic multi-source pharmaceuticals and over-the-counter products through authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC. The scope of work under this code involves supply of pharmaceutical inventory to state health departments, county health systems, and cooperative purchasing organizations supporting multi-state and multi-jurisdictional distribution networks. Issuing bodies include county health departments, state health and human services commissions, and state procurement offices administering cooperative purchasing vehicles. The Texas Health and Human Services Commission posted a Request for Information in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program, indicating exploration of alternative distribution channels beyond traditional pharmacy benefit managers.

Recent activity spans Florida, Minnesota (with Oregon as a participating jurisdiction), and Texas. The Seminole County IFB required responses by July 26, 2023, with quarterly deliveries and vendors responsible for all shipping costs; the MMCAP RFP due March 26, 2026 established a July 1, 2026 contract effective date and weighted price competitiveness at 75 percent of evaluation criteria, requiring vendors to maintain relationships with at least two of three authorized wholesalers and certify compliance with cGMP and Drug Supply Chain Security Act standards. The Minnesota cooperative saw awards effective through June 30, 2028 for incumbent responders, with new responders receiving two-year initial terms and discretionary extensions. Neither the Seminole County nor MMCAP solicitations specified explicit set-aside designations for disadvantaged enterprises. Note that the code's recent opportunities show pharmaceutical supply broadly rather than lonazolac procurement specifically; state and local governments appear to tag pharmaceutical purchases to this Commodity code as a catch-all classification within pharmaceutical taxonomy.